| 1. | streetstock43rac | |
| 2. | lea4582et | |
| 3. | zpc9909 | |
| 4. | mmagwitz | |
| 5. | imaflygirlpilot |
Top Board Researchers
These are the top researchers based on quality of posts as voted by board members. Typically they know their stuff and are a great
way to catch up on what the company is all about.
HOW DO I BECOME ONE?
Just do great research! As other members approve of your posts, you earn points that move you up the ranks.| 1. | streetstock43rac 01/08/2018 a little news - Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value |
| 2. | zpc9909 02/14/2018 Misses EPS loss estimates by $0.15 and misses on revenues |
| 3. | lea4582et 01/17/2018 Agios Announces Proposed Offering of Common Stock - up to $400 million |
| 4. | lea4582et 06/03/2018 Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent |
| 5. | lea4582et 01/18/2018 Pricing of $475 Million Public Offering |
| 6. | streetstock43rac 04/11/2018 Credit Suisse sets PT at $95 |
| 7. | mmagwitz 01/18/2018 Stock rebounded and did better than I thought, down only 3% |
| 8. | streetstock43rac 05/17/2018 Company will present new clinical data from its IDH Programs at ASCO |
| 9. | zpc9909 02/14/2018 Agios Reports Fourth Quarter and Full Year 2017 Financial Results |
| 10. | imaflygirlpilot 02/15/2018 FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation |
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW
Agios Pharmaceuticals, Inc.
- AGIO
- Public Stock Message Board
Filtering by:
-
To use your chart in a post, click the
icon above the chart. From there you can get the chart link or download the image.